Harvest Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Harvest Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,000	Closed	-$117K	–	49
2023 Q3	$117K	Buy	+15,000	New	+$147K	0.06%	46

Other funds holding AUPH

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Harvest Management's AUPH Position: Q4 2023 in Review

Harvest Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2023, closing a stake of 15,000 shares — an estimated $117K sold.

Harvest Management first reported a position in AUPH in Q3 2023 and held it in 1 quarter. The position peaked at $117K in Q3 2023. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2023.

Harvest Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Harvest Management sold 15,000 Aurinia Pharmaceuticals shares in Q4 2023, an estimated $117K.
Harvest Management first reported a position in Aurinia Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Harvest Management's Aurinia Pharmaceuticals position peaked at $117K in Q3 2023.
191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2023.

Based on Harvest Management's 13F filing for Q4 2023, filed 14 Feb 2024.